Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-02-25

FDA Approved: DYANAVEL XR — Supplemental Application (NextWave Pharmaceuticals, Inc)

View source ↗

Summary

The FDA approved a supplemental application for DYANAVEL XR (amphetamine) submitted by NextWave Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dyanavel XR (amphetamine (extended-release))

Snippet

SUPPL AP for DYANAVEL XR (AMPHETAMINE)